Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy

Even if ovarian cancer patients are very responsive to a cisplatinum-based therapy, most will relapse with a resistant disease. New experimental animal models are needed to explore the mechanisms of resistance, to better tailor treatment and improve patient prognosis. To address these aims, seven pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Francesca, Fratelli, Maddalena, Guffanti, Federica, Porcu, Luca, Spriano, Filippo, Dell’Anna, Tiziana, Fruscio, Robert, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352333/
https://www.ncbi.nlm.nih.gov/pubmed/26910918
http://dx.doi.org/10.18632/oncotarget.7465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352333/
https://www.ncbi.nlm.nih.gov/pubmed/26910918
http://dx.doi.org/10.18632/oncotarget.7465

Ejemplares similares